Evogene (NASDAQ: EVGN) has set the date for the release of its second quarter financial results on Thursday 22nd August 2024, before market open. Investors and analysts will have a chance to analyze the company's performance during the quarter.
the enterprise is projected to announce an estimated per share $0.12 loss for the quarter, as predicted by financial analysts on Wall Street. Moreover, the company is expected to disclose a total revenue of $0.8 million for this period.
The earnings report for the corresponding quarter in the previous year showcased a per-share loss of $0.17. This considerable sum was attributed to the company's total revenue, which reached an impressive $0.65 million during that specific quarter.
Wall Street analysts have offered their forecasts for the company's yearly performance, predicting a total revenue of $15.44 million. Additionally, they are expecting the company to report loss of $0.41 per share for the fiscal year 2024.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Q1 2024 | $-0.08 | +46.7% | 4.19 M | +553.7% |
| Q4 2023 | $-0.13 | -85.7% | 0.58 M | -12.4% |
| Q3 2023 | $-0.08 | +50.0% | 3.77 M | +708.4% |
| Q2 2023 | $-0.17 | +19.0% | 0.65 M | +109.6% |
*Growth on year-over-year basis
During the previous trading day, On Wednesday Evogene (EVGN) shares reached a low of $3.87 and a high of $4.04, along with a total volume of 8.40 thousand shares. The stock ended the regular trading session at $3.98, demonstrating downfall of 1.73 percent.
